nodes	percent_of_prediction	percent_of_DWPC	metapath
Mivacurium—Hypoxia—Fludarabine—lymphatic system cancer	0.063	0.063	CcSEcCtD
Mivacurium—Hypoxemia—Methotrexate—lymphatic system cancer	0.0591	0.0591	CcSEcCtD
Mivacurium—Phlebitis—Teniposide—lymphatic system cancer	0.0383	0.0383	CcSEcCtD
Mivacurium—Phlebitis—Fludarabine—lymphatic system cancer	0.0337	0.0337	CcSEcCtD
Mivacurium—Wheezing—Bleomycin—lymphatic system cancer	0.0285	0.0285	CcSEcCtD
Mivacurium—Bronchospasm—Teniposide—lymphatic system cancer	0.0281	0.0281	CcSEcCtD
Mivacurium—Injection site reaction—Carmustine—lymphatic system cancer	0.0255	0.0255	CcSEcCtD
Mivacurium—Phlebitis—Bleomycin—lymphatic system cancer	0.0247	0.0247	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.0228	0.0228	CcSEcCtD
Mivacurium—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.022	0.022	CcSEcCtD
Mivacurium—Phlebitis—Carmustine—lymphatic system cancer	0.0216	0.0216	CcSEcCtD
Mivacurium—Skin disorder—Mechlorethamine—lymphatic system cancer	0.0214	0.0214	CcSEcCtD
Mivacurium—Flushing—Teniposide—lymphatic system cancer	0.0212	0.0212	CcSEcCtD
Mivacurium—Arrhythmia—Teniposide—lymphatic system cancer	0.0204	0.0204	CcSEcCtD
Mivacurium—Phlebitis—Mitoxantrone—lymphatic system cancer	0.0201	0.0201	CcSEcCtD
Mivacurium—Hypoxia—Methotrexate—lymphatic system cancer	0.0187	0.0187	CcSEcCtD
Mivacurium—Bronchospasm—Bleomycin—lymphatic system cancer	0.0181	0.0181	CcSEcCtD
Mivacurium—Arrhythmia—Fludarabine—lymphatic system cancer	0.0179	0.0179	CcSEcCtD
Mivacurium—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.0179	0.0179	CcSEcCtD
Mivacurium—Tachycardia—Teniposide—lymphatic system cancer	0.0158	0.0158	CcSEcCtD
Mivacurium—Hypotension—Teniposide—lymphatic system cancer	0.0152	0.0152	CcSEcCtD
Mivacurium—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.0143	0.0143	CcSEcCtD
Mivacurium—Rash—Mechlorethamine—lymphatic system cancer	0.0139	0.0139	CcSEcCtD
Mivacurium—Dermatitis—Mechlorethamine—lymphatic system cancer	0.0139	0.0139	CcSEcCtD
Mivacurium—Flushing—Bleomycin—lymphatic system cancer	0.0137	0.0137	CcSEcCtD
Mivacurium—Urticaria—Teniposide—lymphatic system cancer	0.0129	0.0129	CcSEcCtD
Mivacurium—Erythema—Bleomycin—lymphatic system cancer	0.0128	0.0128	CcSEcCtD
Mivacurium—Bradycardia—Mitoxantrone—lymphatic system cancer	0.0122	0.0122	CcSEcCtD
Mivacurium—Flushing—Carmustine—lymphatic system cancer	0.0119	0.0119	CcSEcCtD
Mivacurium—Arrhythmia—Carmustine—lymphatic system cancer	0.0115	0.0115	CcSEcCtD
Mivacurium—Cardiac disorder—Vincristine—lymphatic system cancer	0.0114	0.0114	CcSEcCtD
Mivacurium—Erythema—Carmustine—lymphatic system cancer	0.0112	0.0112	CcSEcCtD
Mivacurium—Angiopathy—Vincristine—lymphatic system cancer	0.0111	0.0111	CcSEcCtD
Mivacurium—Mediastinal disorder—Vincristine—lymphatic system cancer	0.0111	0.0111	CcSEcCtD
Mivacurium—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.0107	0.0107	CcSEcCtD
Mivacurium—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.0105	0.0105	CcSEcCtD
Mivacurium—Erythema—Mitoxantrone—lymphatic system cancer	0.0104	0.0104	CcSEcCtD
Mivacurium—Rash—Teniposide—lymphatic system cancer	0.0102	0.0102	CcSEcCtD
Mivacurium—Dermatitis—Teniposide—lymphatic system cancer	0.0102	0.0102	CcSEcCtD
Mivacurium—Hypotension—Bleomycin—lymphatic system cancer	0.00978	0.00978	CcSEcCtD
Mivacurium—Rash—Fludarabine—lymphatic system cancer	0.009	0.009	CcSEcCtD
Mivacurium—Dermatitis—Fludarabine—lymphatic system cancer	0.00899	0.00899	CcSEcCtD
Mivacurium—Tachycardia—Carmustine—lymphatic system cancer	0.00891	0.00891	CcSEcCtD
Mivacurium—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00889	0.00889	CcSEcCtD
Mivacurium—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00872	0.00872	CcSEcCtD
Mivacurium—Hypotension—Carmustine—lymphatic system cancer	0.00853	0.00853	CcSEcCtD
Mivacurium—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00849	0.00849	CcSEcCtD
Mivacurium—Urticaria—Bleomycin—lymphatic system cancer	0.00831	0.00831	CcSEcCtD
Mivacurium—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00829	0.00829	CcSEcCtD
Mivacurium—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00825	0.00825	CcSEcCtD
Mivacurium—Hypotension—Vincristine—lymphatic system cancer	0.00815	0.00815	CcSEcCtD
Mivacurium—Hypotension—Mitoxantrone—lymphatic system cancer	0.00793	0.00793	CcSEcCtD
Mivacurium—Urticaria—Mitoxantrone—lymphatic system cancer	0.00675	0.00675	CcSEcCtD
Mivacurium—Rash—Bleomycin—lymphatic system cancer	0.0066	0.0066	CcSEcCtD
Mivacurium—Dermatitis—Bleomycin—lymphatic system cancer	0.00659	0.00659	CcSEcCtD
Mivacurium—Dizziness—Carmustine—lymphatic system cancer	0.00604	0.00604	CcSEcCtD
Mivacurium—Dizziness—Vincristine—lymphatic system cancer	0.00577	0.00577	CcSEcCtD
Mivacurium—Rash—Carmustine—lymphatic system cancer	0.00576	0.00576	CcSEcCtD
Mivacurium—Dermatitis—Carmustine—lymphatic system cancer	0.00575	0.00575	CcSEcCtD
Mivacurium—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00553	0.00553	CcSEcCtD
Mivacurium—Rash—Vincristine—lymphatic system cancer	0.0055	0.0055	CcSEcCtD
Mivacurium—Dermatitis—Vincristine—lymphatic system cancer	0.00549	0.00549	CcSEcCtD
Mivacurium—Angiopathy—Methotrexate—lymphatic system cancer	0.0054	0.0054	CcSEcCtD
Mivacurium—Immune system disorder—Methotrexate—lymphatic system cancer	0.00538	0.00538	CcSEcCtD
Mivacurium—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00537	0.00537	CcSEcCtD
Mivacurium—Rash—Mitoxantrone—lymphatic system cancer	0.00535	0.00535	CcSEcCtD
Mivacurium—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00535	0.00535	CcSEcCtD
Mivacurium—Erythema—Methotrexate—lymphatic system cancer	0.00518	0.00518	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00438	0.00438	CcSEcCtD
Mivacurium—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Mivacurium—Skin disorder—Methotrexate—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Mivacurium—Hypotension—Methotrexate—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Mivacurium—Urticaria—Methotrexate—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Mivacurium—Dizziness—Methotrexate—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Mivacurium—Rash—Methotrexate—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Mivacurium—Dermatitis—Methotrexate—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
